PR+ breast cancer responds well to hormone therapy, underscoring the need for molecular insight and targeted treatment strategies.

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements.

Maternal stress is a major risk factor for preterm birth (PTB), with recent mouse studies highlighting the role of FKBP51 in ...

Evolution in women's cancer diagnostics: from histopathology to molecular testing, personalized treatment for breast, ovarian ...

A meta-analysis of 102 studies and 3,943 participants found no significant cognitive differences across menstrual phases.

Triple negative breast cancer accounts for 15% of cases but causes a disproportionate number of deaths. Learn about symptoms ...

Too few people get diagnosed and treated for postpartum depression. But a blood test could change that Postpartum depression ...

Recent advancements in endometriosis research are transforming treatment, focusing on non-surgical interventions and ...

Firas Eladoumikdachi, MD, FACS, and M. Michele Blackwood, MD, FACS, assess preoperative radiation boosts in breast cancer care.

The wedding comes just weeks after Thurston, who starred in season 17 of "The Bachelorette," revealed in an emotional ...

Discover why some women develop fibroids while others don't, from genetics and hormones to lifestyle and environmental ...